Background: There are few publications on anemia following artesunate treatment. Objective: To investigate the hemoglobin in patients with severe Plasmodium falciparum malaria treated with artesunate or quinine. Methods: Patients with P. falciparum (in Singa, Sudan) were treated by intravenous artesunate or quinine. Hemoglobin was measured initially, at day 14 and day 28. Results: The mean (SD) of the age was 10.3 (10.9) years. The two groups (61 in each arm) were matched in their basic characteristics. Hypotension, convulsions, severe anemia were the main presentations. There was no significant difference in the mean (SD) hemoglobin level at the initial day, day 14 and at day
I N T R O D U C T I O N
Severe malaria is a big health problem and-if untreated-is fatal in the majority of cases [1] . The World Health Organization (WHO) recommends parenteral artesunate, alternatively artemether in preference to quinine for treatment of severe Plasmodium falciparum malaria for all age groups and in all settings [2] .
In Sudan it has been estimated that there were 9 million malaria episodes and 44 000 malariaattributed death [3] . Artemisinin-based combination drugs and quinine are the first-line treatment of uncomplicated and severe malaria, respectively [4] . Several studies documented artesunate safety compared with quinine [5] [6] [7] [8] . However, anemiaespecially hemolytic one-following parenteral artesunate therapy in patients with severe P. falciparum malaria was recently reported [9] [10] [11] [12] [13] [14] . The majority of these reports were case series and from nonimmune European travelers [9] [10] [11] [12] [13] and few of them were scant African reports [14] . Thus, anemia/ reduction of hemoglobin following parenteral artesunate therapy in patients with severe P. falciparum needs to be explored further especially in different V C The Author [2016] . Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com malaria endemic settings. The current study was conducted at Singa hospital, Sudan, which is characterized by unstable malaria transmission (seasonal) and P. falciparum is the main malaria species [15] . Such research is fundamental to yield necessary data for both care givers and health planners and to add to our ongoing research on treatment of severe P. falciparum malaria in Sudan [6, 16] .
M E T H O D S
Following the previous studies [6, 16] that were registered, 'NCT01805232', an open clinical trial was conducted during the post rainy season (AugustDecember) at Singa Hospital, Sudan to investigate the operational part of the intravenous artesunate and to investigate the difference of hemoglobin level at the base, day 14 and day 28. The details of methods were described in our previous work [6, 16] . In summary, patients who have been admitted to the hospital with slide-confirmed, severe P. falciparum malaria were recruited after written informed consent was obtained from the patients or their parent or guardian. Any identifiable cause of anemia (nutritional and worm infection) other than malaria was an exclusion criterion. Patients were resuscitated and supportive care was offered to them according to the WHO guidelines of management of severe malaria [2] . Patients were allocated randomly to receive either of the two drugs (artesunate or quinine) using predetermined computer-generated numbers. Artesunate (Guilin Pharmaceuticals, Shanghai, China) was prepared and administered intravenously at a dose of 2.4 mg/kg body weight at 0, 12 and 24 h, and then daily. Quinine (Shanghai, China) was infused initially in a loading dose of 20 mg/kg over 4 h, then 10 mg/kg over 2-4 h three times a day. The patients, when tolerating, continued their measures was performed for the hemoglobin level at presentation, day 14 and day 28. A p < 0.05 was considered significant.
R E S U L T S Hundred twenty-two (61 in each arm of the study) were enrolled in the study. The two groups (artesunate and quinine) were well matched in their basic characteristics, Table 1 . There were 39 (63.9%) and 38 (62.3%), p ¼ 0.500 males in the artesunate and quinine groups, respectively. Hypotension, repeated convulsions, severe anemia, hypoglycemia and cerebral malaria were the main presentations of severe malaria and these were not different between the two groups, Table 2 . None of the patients received blood transfusion.
Thirty-nine patients were lost on follow-up at day 14 and 28 owing to change of the address, Fig. 1 . There was no significant difference in the mean (SD) of hemoglobin level at the initial, day 14 and at day 28 [11.2 (1.8), 11.3 (1.6), 11.5 (1.8), p ¼ 0.170], respectively, in all study groups. Likewise, the mean (SD) hemoglobin level did not change significantly from the baseline in any group of the study (artesunate or quinine); Table 3 , Fig. 2 .
D I S C U S S I O N
This study demonstrated no difference in hemoglobin level in patients with severe P. falciparum malaria at 7 and 28 days following treatment with artesunate or quinine. Recently, hemolytic and reduction of hemoglobin was reported among non-immunized European [9] [10] [11] [12] [13] [14] and immunized African patients [17] [18] [19] [20] . It is worth to be mentioned that systemic review documented that 37 patients had hemolysis following the treatment of severe malaria treated with artemisinin derivatives [14] . Of these, 31 (83.7%) received intravenous artesunate, while the rest (6) received parenteral or oral regimens of artemisinin derivatives. The majority of patients were returning travelers. The reduction of hemoglobin owing to hemolysis was 6 g/dl [14] .
The current study and the other studies should be compared cautiously because of the difference in the malaria endemicity. Furthermore, the previous studies used LDH as a marker of hemolysis though risking the specificity, as it is a nonspecific marker of hemolysis because it was reported in patients with severe malaria without evidence of anemia [18] . Malaria is a known cause of anemia besides anemia is one of the criteria of the definition of severe malaria [2] . Sowunmi et al. reported both increase and fall, which may or may not be associated with anemia in children with uncomplicated malaria treated with artemisinin combination therapy [21] . Owing to the conflicting reports, further large-scale studies are needed to confirm or refute artesunate-associated anemia, especially hemolytic in malaria-endemic areas. The limitations of this study were small sample study, high dropout, indices of hemolysis were not measured because many reports established an association between treatment with artesunate and hemolysis in patients with severe malaria [9] [10] [11] [12] [13] and the other causes of anemia, as potential confounders, such as nutritional causes were not measured in this study.
C O N C L U S I O N
No difference in hemoglobin concentration in patients with severe malaria at 2 and 4 weeks after treatment with either artesunate or quinine.
